Secukinumab vs Adalimumab for The Treatment of Psoriatic Arthritis- A Cost Per Responder Analysis At 48 Weeks from A Chilean Perspective

Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.2974
https://www.valueinhealthjournal.com/article/S1098-3015(17)33308-9/fulltext
Title : Secukinumab vs Adalimumab for The Treatment of Psoriatic Arthritis- A Cost Per Responder Analysis At 48 Weeks from A Chilean Perspective
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)33308-9&doi=10.1016/j.jval.2017.08.2974
First page : A937
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 2721
Categories :
Tags :
Regions :
ViH Article Tags :